Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial
B-cell acute lymphoblastic leukemia (B-ALL) is rare in adults but the prognosis remains inferior to children. To comprehensively define the genomic landscape of B-ALL in adults, we analyzed 569 cases by transcriptome, genome and exome sequencing. Our integrated genomic analyses identified 22 molecular subtypes of adult B-ALL, with an additional 268 driver genes identified as secondary genomic alterations that contributed to the enrichment of significantly altered biological pathways. We identified a subgroup of adult B-ALL characterized by overexpression of CEBPA or CEBPB in 3.5% of cases by a variety of genomic mechanisms including chromosomal translocation and noncoding mutations that result in enhancer hijacking or the formation of de novo enhancers downstream of CEBPA. The addition of blinatumomab to chemotherapy improved the outcome for several high-risk B-ALL subgroups, including hyperdiploid, PAX5alt, PAX5 P80R, BCR::ABL1-like with CRLF2 rearrangements and KMT2A-rearranged ALL. Alteration of TP53 or mutations associated with myeloid clonal hematopoiesis (MyM) were identified in 15.3% and 9.8% of patients assessed, respectively. The presence of these mutations was associated with increased age at diagnosis and inferior outcome to chemotherapy, whilst blinatumomab rescued this poor outcome, especially for patients with MyM. Together we provide a comprehensive genomic analysis of adult B-ALL and provide guidance on the use of blinatumomab in high-risk subtypes.
- Type: Cancer Genomics
- Archive: European Genome-phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD50000002271 | Illumina NovaSeq X | 230 | |
| EGAD50000002511 | Illumina NovaSeq X | 218 | |
| EGAD50000002772 | Illumina NovaSeq X | 808 |
| Publications | Citations |
|---|---|
|
Genomic drivers of leukemia and blinatumomab response in adult acute lymphoblastic leukemia - the ECOG-ACRIN E1910 study.
Blood None: 2026 blood.2026033793 |
0 |
